Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS)
Identifieur interne : 000613 ( Istex/Corpus ); précédent : 000612; suivant : 000614Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS)
Auteurs : Gregor K. Wenning ; Franc Ois Tison ; Klaus Seppi ; Cristina Sampaio ; Anja Diem ; Farid Yekhlef ; Imad Ghorayeb ; Fabienne Ory ; Monique Galitzky ; Tommaso Scaravilli ; Maria Bozi ; Carlo Colosimo ; Sid Gilman ; Clifford W. Shults ; Niall P. Quinn ; Olivier Rascol ; Werner PoeweSource :
- Movement Disorders [ 0885-3185 ] ; 2004-12.
English descriptors
- KwdEn :
Abstract
We aimed to develop and validate a novel rating scale for multiple system atrophy (Unified Multiple System Atrophy Rating Scale ‐ UMSARS). The scale comprises the following components: Part I, historical, 12 items; Part II, motor examination, 14 items; Part III, autonomic examination; and Part IV, global disability scale. For validation purposes, 40 MSA patients were assessed in four centers by 4 raters per center (2 senior and 2 junior raters). The raters applied the UMSARS, as well as a range of other scales, including the Unified Parkinson's Disease Rating Scale (UPDRS) and the International Cooperative Ataxia Rating Scale (ICARS). Internal consistency was high for both UMSARS‐I (Crohnbach's alpha = 0.84) and UMSARS‐II (Crohnbach's alpha = 0.90) sections. The interrater reliability of most of the UMSARS‐I and ‐II items as well as of total UMSARS‐I and ‐II subscores was substantial (k (w) = 0.6–0.8) to excellent (k (w) > 0.8). UMSARS‐II correlated well with UPDRS‐III and ICARS (rs > 0.8). Depending on the degree of the patient's disability, completion of the entire UMSARS took 30 to 45 minutes. Based on our findings, the UMSARS appears to be a multidimensional, reliable, and valid scale for semiquantitative clinical assessments of MSA patients. © 2004 Movement Disorder Society
Url:
DOI: 10.1002/mds.20255
Links to Exploration step
ISTEX:2C01987595DEF441D78B1D1D9A34624282EBF9BALe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS)</title><author><name sortKey="Wenning, Gregor K" sort="Wenning, Gregor K" uniqKey="Wenning G" first="Gregor K." last="Wenning">Gregor K. Wenning</name><affiliation><mods:affiliation>Department of Neurology, University of Innsbruck, Austria</mods:affiliation></affiliation></author><author><name sortKey="Tison, Franc Ois" sort="Tison, Franc Ois" uniqKey="Tison F" first="Franc Ois" last="Tison">Franc Ois Tison</name><affiliation><mods:affiliation>Service de Neurologie, Hopital du Haut‐Leveque, Pessac, France</mods:affiliation></affiliation></author><author><name sortKey="Seppi, Klaus" sort="Seppi, Klaus" uniqKey="Seppi K" first="Klaus" last="Seppi">Klaus Seppi</name><affiliation><mods:affiliation>Department of Neurology, University of Innsbruck, Austria</mods:affiliation></affiliation></author><author><name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name><affiliation><mods:affiliation>Faculdade de Medicine de Lisboa, Hospital Santa Maria, Centro de Neurosciencas, Lisboa, Portugal</mods:affiliation></affiliation></author><author><name sortKey="Diem, Anja" sort="Diem, Anja" uniqKey="Diem A" first="Anja" last="Diem">Anja Diem</name><affiliation><mods:affiliation>Department of Neurology, University of Innsbruck, Austria</mods:affiliation></affiliation></author><author><name sortKey="Yekhlef, Farid" sort="Yekhlef, Farid" uniqKey="Yekhlef F" first="Farid" last="Yekhlef">Farid Yekhlef</name><affiliation><mods:affiliation>Service de Neurologie, Hopital du Haut‐Leveque, Pessac, France</mods:affiliation></affiliation></author><author><name sortKey="Ghorayeb, Imad" sort="Ghorayeb, Imad" uniqKey="Ghorayeb I" first="Imad" last="Ghorayeb">Imad Ghorayeb</name><affiliation><mods:affiliation>Service de Neurologie, Hopital du Haut‐Leveque, Pessac, France</mods:affiliation></affiliation></author><author><name sortKey="Ory, Fabienne" sort="Ory, Fabienne" uniqKey="Ory F" first="Fabienne" last="Ory">Fabienne Ory</name><affiliation><mods:affiliation>Toulouse III University, Laboratoire de Pharmacologie, Faculte de Medecine, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Galitzky, Monique" sort="Galitzky, Monique" uniqKey="Galitzky M" first="Monique" last="Galitzky">Monique Galitzky</name><affiliation><mods:affiliation>Toulouse III University, Laboratoire de Pharmacologie, Faculte de Medecine, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Scaravilli, Tommaso" sort="Scaravilli, Tommaso" uniqKey="Scaravilli T" first="Tommaso" last="Scaravilli">Tommaso Scaravilli</name><affiliation><mods:affiliation>University College London, Institute of Neurology, Queen Square, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Bozi, Maria" sort="Bozi, Maria" uniqKey="Bozi M" first="Maria" last="Bozi">Maria Bozi</name><affiliation><mods:affiliation>University College London, Institute of Neurology, Queen Square, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Colosimo, Carlo" sort="Colosimo, Carlo" uniqKey="Colosimo C" first="Carlo" last="Colosimo">Carlo Colosimo</name><affiliation><mods:affiliation>Dipartimento di Scienze Neurologiche, Universita' La Sapienza, Rome, Italy</mods:affiliation></affiliation></author><author><name sortKey="Gilman, Sid" sort="Gilman, Sid" uniqKey="Gilman S" first="Sid" last="Gilman">Sid Gilman</name><affiliation><mods:affiliation>Department of Neurology, University of Michigan, Ann Arbor, Michigan, USA</mods:affiliation></affiliation></author><author><name sortKey="Shults, Clifford W" sort="Shults, Clifford W" uniqKey="Shults C" first="Clifford W." last="Shults">Clifford W. Shults</name><affiliation><mods:affiliation>Department of Neurosciences, University of California San Diego School of Medicine, La Jolla, California, USA</mods:affiliation></affiliation></author><author><name sortKey="Quinn, Niall P" sort="Quinn, Niall P" uniqKey="Quinn N" first="Niall P." last="Quinn">Niall P. Quinn</name><affiliation><mods:affiliation>University College London, Institute of Neurology, Queen Square, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation><mods:affiliation>Toulouse III University, Laboratoire de Pharmacologie, Faculte de Medecine, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name><affiliation><mods:affiliation>Department of Neurology, University of Innsbruck, Austria</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:2C01987595DEF441D78B1D1D9A34624282EBF9BA</idno><date when="2004" year="2004">2004</date><idno type="doi">10.1002/mds.20255</idno><idno type="url">https://api.istex.fr/document/2C01987595DEF441D78B1D1D9A34624282EBF9BA/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000613</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS)</title><author><name sortKey="Wenning, Gregor K" sort="Wenning, Gregor K" uniqKey="Wenning G" first="Gregor K." last="Wenning">Gregor K. Wenning</name><affiliation><mods:affiliation>Department of Neurology, University of Innsbruck, Austria</mods:affiliation></affiliation></author><author><name sortKey="Tison, Franc Ois" sort="Tison, Franc Ois" uniqKey="Tison F" first="Franc Ois" last="Tison">Franc Ois Tison</name><affiliation><mods:affiliation>Service de Neurologie, Hopital du Haut‐Leveque, Pessac, France</mods:affiliation></affiliation></author><author><name sortKey="Seppi, Klaus" sort="Seppi, Klaus" uniqKey="Seppi K" first="Klaus" last="Seppi">Klaus Seppi</name><affiliation><mods:affiliation>Department of Neurology, University of Innsbruck, Austria</mods:affiliation></affiliation></author><author><name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name><affiliation><mods:affiliation>Faculdade de Medicine de Lisboa, Hospital Santa Maria, Centro de Neurosciencas, Lisboa, Portugal</mods:affiliation></affiliation></author><author><name sortKey="Diem, Anja" sort="Diem, Anja" uniqKey="Diem A" first="Anja" last="Diem">Anja Diem</name><affiliation><mods:affiliation>Department of Neurology, University of Innsbruck, Austria</mods:affiliation></affiliation></author><author><name sortKey="Yekhlef, Farid" sort="Yekhlef, Farid" uniqKey="Yekhlef F" first="Farid" last="Yekhlef">Farid Yekhlef</name><affiliation><mods:affiliation>Service de Neurologie, Hopital du Haut‐Leveque, Pessac, France</mods:affiliation></affiliation></author><author><name sortKey="Ghorayeb, Imad" sort="Ghorayeb, Imad" uniqKey="Ghorayeb I" first="Imad" last="Ghorayeb">Imad Ghorayeb</name><affiliation><mods:affiliation>Service de Neurologie, Hopital du Haut‐Leveque, Pessac, France</mods:affiliation></affiliation></author><author><name sortKey="Ory, Fabienne" sort="Ory, Fabienne" uniqKey="Ory F" first="Fabienne" last="Ory">Fabienne Ory</name><affiliation><mods:affiliation>Toulouse III University, Laboratoire de Pharmacologie, Faculte de Medecine, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Galitzky, Monique" sort="Galitzky, Monique" uniqKey="Galitzky M" first="Monique" last="Galitzky">Monique Galitzky</name><affiliation><mods:affiliation>Toulouse III University, Laboratoire de Pharmacologie, Faculte de Medecine, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Scaravilli, Tommaso" sort="Scaravilli, Tommaso" uniqKey="Scaravilli T" first="Tommaso" last="Scaravilli">Tommaso Scaravilli</name><affiliation><mods:affiliation>University College London, Institute of Neurology, Queen Square, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Bozi, Maria" sort="Bozi, Maria" uniqKey="Bozi M" first="Maria" last="Bozi">Maria Bozi</name><affiliation><mods:affiliation>University College London, Institute of Neurology, Queen Square, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Colosimo, Carlo" sort="Colosimo, Carlo" uniqKey="Colosimo C" first="Carlo" last="Colosimo">Carlo Colosimo</name><affiliation><mods:affiliation>Dipartimento di Scienze Neurologiche, Universita' La Sapienza, Rome, Italy</mods:affiliation></affiliation></author><author><name sortKey="Gilman, Sid" sort="Gilman, Sid" uniqKey="Gilman S" first="Sid" last="Gilman">Sid Gilman</name><affiliation><mods:affiliation>Department of Neurology, University of Michigan, Ann Arbor, Michigan, USA</mods:affiliation></affiliation></author><author><name sortKey="Shults, Clifford W" sort="Shults, Clifford W" uniqKey="Shults C" first="Clifford W." last="Shults">Clifford W. Shults</name><affiliation><mods:affiliation>Department of Neurosciences, University of California San Diego School of Medicine, La Jolla, California, USA</mods:affiliation></affiliation></author><author><name sortKey="Quinn, Niall P" sort="Quinn, Niall P" uniqKey="Quinn N" first="Niall P." last="Quinn">Niall P. Quinn</name><affiliation><mods:affiliation>University College London, Institute of Neurology, Queen Square, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation><mods:affiliation>Toulouse III University, Laboratoire de Pharmacologie, Faculte de Medecine, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name><affiliation><mods:affiliation>Department of Neurology, University of Innsbruck, Austria</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2004-12">2004-12</date><biblScope unit="vol">19</biblScope><biblScope unit="issue">12</biblScope><biblScope unit="page" from="1391">1391</biblScope><biblScope unit="page" to="1402">1402</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">2C01987595DEF441D78B1D1D9A34624282EBF9BA</idno><idno type="DOI">10.1002/mds.20255</idno><idno type="ArticleID">MDS20255</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Unified Multiple System Atrophy Rating Scale</term><term>internal consistency</term><term>interrater reliability</term><term>validation</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We aimed to develop and validate a novel rating scale for multiple system atrophy (Unified Multiple System Atrophy Rating Scale ‐ UMSARS). The scale comprises the following components: Part I, historical, 12 items; Part II, motor examination, 14 items; Part III, autonomic examination; and Part IV, global disability scale. For validation purposes, 40 MSA patients were assessed in four centers by 4 raters per center (2 senior and 2 junior raters). The raters applied the UMSARS, as well as a range of other scales, including the Unified Parkinson's Disease Rating Scale (UPDRS) and the International Cooperative Ataxia Rating Scale (ICARS). Internal consistency was high for both UMSARS‐I (Crohnbach's alpha = 0.84) and UMSARS‐II (Crohnbach's alpha = 0.90) sections. The interrater reliability of most of the UMSARS‐I and ‐II items as well as of total UMSARS‐I and ‐II subscores was substantial (k (w) = 0.6–0.8) to excellent (k (w) > 0.8). UMSARS‐II correlated well with UPDRS‐III and ICARS (rs > 0.8). Depending on the degree of the patient's disability, completion of the entire UMSARS took 30 to 45 minutes. Based on our findings, the UMSARS appears to be a multidimensional, reliable, and valid scale for semiquantitative clinical assessments of MSA patients. © 2004 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Gregor K. Wenning MD, PhD</name><affiliations><json:string>Department of Neurology, University of Innsbruck, Austria</json:string></affiliations></json:item><json:item><name>Franc̨ois Tison MD</name><affiliations><json:string>Service de Neurologie, Hopital du Haut‐Leveque, Pessac, France</json:string></affiliations></json:item><json:item><name>Klaus Seppi MD</name><affiliations><json:string>Department of Neurology, University of Innsbruck, Austria</json:string></affiliations></json:item><json:item><name>Cristina Sampaio MD</name><affiliations><json:string>Faculdade de Medicine de Lisboa, Hospital Santa Maria, Centro de Neurosciencas, Lisboa, Portugal</json:string></affiliations></json:item><json:item><name>Anja Diem MD</name><affiliations><json:string>Department of Neurology, University of Innsbruck, Austria</json:string></affiliations></json:item><json:item><name>Farid Yekhlef MD</name><affiliations><json:string>Service de Neurologie, Hopital du Haut‐Leveque, Pessac, France</json:string></affiliations></json:item><json:item><name>Imad Ghorayeb MD</name><affiliations><json:string>Service de Neurologie, Hopital du Haut‐Leveque, Pessac, France</json:string></affiliations></json:item><json:item><name>Fabienne Ory MD</name><affiliations><json:string>Toulouse III University, Laboratoire de Pharmacologie, Faculte de Medecine, Toulouse, France</json:string></affiliations></json:item><json:item><name>Monique Galitzky MD</name><affiliations><json:string>Toulouse III University, Laboratoire de Pharmacologie, Faculte de Medecine, Toulouse, France</json:string></affiliations></json:item><json:item><name>Tommaso Scaravilli MD</name><affiliations><json:string>University College London, Institute of Neurology, Queen Square, London, United Kingdom</json:string></affiliations></json:item><json:item><name>Maria Bozi MD</name><affiliations><json:string>University College London, Institute of Neurology, Queen Square, London, United Kingdom</json:string></affiliations></json:item><json:item><name>Carlo Colosimo MD</name><affiliations><json:string>Dipartimento di Scienze Neurologiche, Universita' La Sapienza, Rome, Italy</json:string></affiliations></json:item><json:item><name>Sid Gilman MD</name><affiliations><json:string>Department of Neurology, University of Michigan, Ann Arbor, Michigan, USA</json:string></affiliations></json:item><json:item><name>Clifford W. Shults MD</name><affiliations><json:string>Department of Neurosciences, University of California San Diego School of Medicine, La Jolla, California, USA</json:string></affiliations></json:item><json:item><name>Niall P. Quinn MD</name><affiliations><json:string>University College London, Institute of Neurology, Queen Square, London, United Kingdom</json:string></affiliations></json:item><json:item><name>Olivier Rascol MD</name><affiliations><json:string>Toulouse III University, Laboratoire de Pharmacologie, Faculte de Medecine, Toulouse, France</json:string></affiliations></json:item><json:item><name>Werner Poewe MD</name><affiliations><json:string>Department of Neurology, University of Innsbruck, Austria</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Unified Multiple System Atrophy Rating Scale</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>validation</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>internal consistency</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>interrater reliability</value></json:item></subject><language><json:string>eng</json:string></language><abstract>We aimed to develop and validate a novel rating scale for multiple system atrophy (Unified Multiple System Atrophy Rating Scale ‐ UMSARS). The scale comprises the following components: Part I, historical, 12 items; Part II, motor examination, 14 items; Part III, autonomic examination; and Part IV, global disability scale. For validation purposes, 40 MSA patients were assessed in four centers by 4 raters per center (2 senior and 2 junior raters). The raters applied the UMSARS, as well as a range of other scales, including the Unified Parkinson's Disease Rating Scale (UPDRS) and the International Cooperative Ataxia Rating Scale (ICARS). Internal consistency was high for both UMSARS‐I (Crohnbach's alpha = 0.84) and UMSARS‐II (Crohnbach's alpha = 0.90) sections. The interrater reliability of most of the UMSARS‐I and ‐II items as well as of total UMSARS‐I and ‐II subscores was substantial (k (w) = 0.6–0.8) to excellent (k (w) > 0.8). UMSARS‐II correlated well with UPDRS‐III and ICARS (rs > 0.8). Depending on the degree of the patient's disability, completion of the entire UMSARS took 30 to 45 minutes. Based on our findings, the UMSARS appears to be a multidimensional, reliable, and valid scale for semiquantitative clinical assessments of MSA patients. © 2004 Movement Disorder Society</abstract><qualityIndicators><score>7.46</score><pdfVersion>1.3</pdfVersion><pdfPageSize>594 x 792 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>1299</abstractCharCount><pdfWordCount>6557</pdfWordCount><pdfCharCount>43547</pdfCharCount><pdfPageCount>12</pdfPageCount><abstractWordCount>205</abstractWordCount></qualityIndicators><title>Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS)</title><corporate><json:item><name></name><affiliations><json:string>Department of Neurology, University of Innsbruck, Austria</json:string><json:string>Service de Neurologie, Hopital du Haut‐Leveque, Pessac, France</json:string><json:string>Faculdade de Medicine de Lisboa, Hospital Santa Maria, Centro de Neurosciencas, Lisboa, Portugal</json:string><json:string>Toulouse III University, Laboratoire de Pharmacologie, Faculte de Medecine, Toulouse, France</json:string><json:string>University College London, Institute of Neurology, Queen Square, London, United Kingdom</json:string><json:string>Dipartimento di Scienze Neurologiche, Universita' La Sapienza, Rome, Italy</json:string><json:string>Department of Neurology, University of Michigan, Ann Arbor, Michigan, USA</json:string><json:string>Department of Neurosciences, University of California San Diego School of Medicine, La Jolla, California, USA</json:string></affiliations></json:item></corporate><genre><json:string>Serial article</json:string></genre><host><volume>19</volume><pages><total>13</total><last>1402</last><first>1391</first></pages><issn><json:string>0885-3185</json:string></issn><issue>12</issue><subject><json:item><value>Research Article</value></json:item></subject><genre></genre><language><json:string>unknown</json:string></language><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2004</publicationDate><copyrightDate>2004</copyrightDate><doi><json:string>10.1002/mds.20255</json:string></doi><id>2C01987595DEF441D78B1D1D9A34624282EBF9BA</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/2C01987595DEF441D78B1D1D9A34624282EBF9BA/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/2C01987595DEF441D78B1D1D9A34624282EBF9BA/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/2C01987595DEF441D78B1D1D9A34624282EBF9BA/fulltext/tei"><teiHeader type="text"><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS)</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>Wiley Subscription Services, Inc., A Wiley Company</p></availability><date>2004</date></publicationStmt><notesStmt><note>EC - No. QLK6‐2000‐00661;</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS)</title><author><orgName>and the Multiple System Atrophy Study Group</orgName><affiliation>Department of Neurology, University of Innsbruck, Austria</affiliation><affiliation>Service de Neurologie, Hopital du Haut‐Leveque, Pessac, France</affiliation><affiliation>Faculdade de Medicine de Lisboa, Hospital Santa Maria, Centro de Neurosciencas, Lisboa, Portugal</affiliation><affiliation>Toulouse III University, Laboratoire de Pharmacologie, Faculte de Medecine, Toulouse, France</affiliation><affiliation>University College London, Institute of Neurology, Queen Square, London, United Kingdom</affiliation><affiliation>Dipartimento di Scienze Neurologiche, Universita' La Sapienza, Rome, Italy</affiliation><affiliation>Department of Neurology, University of Michigan, Ann Arbor, Michigan, USA</affiliation><affiliation>Department of Neurosciences, University of California San Diego School of Medicine, La Jolla, California, USA</affiliation></author><author><persName><forename type="first">Gregor K.</forename><surname>Wenning</surname><roleName type="degree">MD, PhD</roleName></persName><note type="biography">Drs. Wenning and Tison contributed equally to this study.</note><affiliation>Drs. Wenning and Tison contributed equally to this study.</affiliation><note type="correspondence"><p>Correspondence: Department of Neurology. University of Innsbruck, A‐6020 Innsbruck, Austria</p></note><affiliation>Department of Neurology, University of Innsbruck, Austria</affiliation></author><author><persName><forename type="first">Franc̨ois</forename><surname>Tison</surname><roleName type="degree">MD</roleName></persName><note type="biography">Drs. Wenning and Tison contributed equally to this study.</note><affiliation>Drs. Wenning and Tison contributed equally to this study.</affiliation><affiliation>Service de Neurologie, Hopital du Haut‐Leveque, Pessac, France</affiliation></author><author><persName><forename type="first">Klaus</forename><surname>Seppi</surname><roleName type="degree">MD</roleName></persName><affiliation>Department of Neurology, University of Innsbruck, Austria</affiliation></author><author><persName><forename type="first">Cristina</forename><surname>Sampaio</surname><roleName type="degree">MD</roleName></persName><affiliation>Faculdade de Medicine de Lisboa, Hospital Santa Maria, Centro de Neurosciencas, Lisboa, Portugal</affiliation></author><author><persName><forename type="first">Anja</forename><surname>Diem</surname><roleName type="degree">MD</roleName></persName><affiliation>Department of Neurology, University of Innsbruck, Austria</affiliation></author><author><persName><forename type="first">Farid</forename><surname>Yekhlef</surname><roleName type="degree">MD</roleName></persName><affiliation>Service de Neurologie, Hopital du Haut‐Leveque, Pessac, France</affiliation></author><author><persName><forename type="first">Imad</forename><surname>Ghorayeb</surname><roleName type="degree">MD</roleName></persName><affiliation>Service de Neurologie, Hopital du Haut‐Leveque, Pessac, France</affiliation></author><author><persName><forename type="first">Fabienne</forename><surname>Ory</surname><roleName type="degree">MD</roleName></persName><affiliation>Toulouse III University, Laboratoire de Pharmacologie, Faculte de Medecine, Toulouse, France</affiliation></author><author><persName><forename type="first">Monique</forename><surname>Galitzky</surname><roleName type="degree">MD</roleName></persName><affiliation>Toulouse III University, Laboratoire de Pharmacologie, Faculte de Medecine, Toulouse, France</affiliation></author><author><persName><forename type="first">Tommaso</forename><surname>Scaravilli</surname><roleName type="degree">MD</roleName></persName><affiliation>University College London, Institute of Neurology, Queen Square, London, United Kingdom</affiliation></author><author><persName><forename type="first">Maria</forename><surname>Bozi</surname><roleName type="degree">MD</roleName></persName><affiliation>University College London, Institute of Neurology, Queen Square, London, United Kingdom</affiliation></author><author><persName><forename type="first">Carlo</forename><surname>Colosimo</surname><roleName type="degree">MD</roleName></persName><affiliation>Dipartimento di Scienze Neurologiche, Universita' La Sapienza, Rome, Italy</affiliation></author><author><persName><forename type="first">Sid</forename><surname>Gilman</surname><roleName type="degree">MD</roleName></persName><affiliation>Department of Neurology, University of Michigan, Ann Arbor, Michigan, USA</affiliation></author><author><persName><forename type="first">Clifford W.</forename><surname>Shults</surname><roleName type="degree">MD</roleName></persName><affiliation>Department of Neurosciences, University of California San Diego School of Medicine, La Jolla, California, USA</affiliation></author><author><persName><forename type="first">Niall P.</forename><surname>Quinn</surname><roleName type="degree">MD</roleName></persName><affiliation>University College London, Institute of Neurology, Queen Square, London, United Kingdom</affiliation></author><author><persName><forename type="first">Olivier</forename><surname>Rascol</surname><roleName type="degree">MD</roleName></persName><affiliation>Toulouse III University, Laboratoire de Pharmacologie, Faculte de Medecine, Toulouse, France</affiliation></author><author><persName><forename type="first">Werner</forename><surname>Poewe</surname><roleName type="degree">MD</roleName></persName><affiliation>Department of Neurology, University of Innsbruck, Austria</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2004-12"></date><biblScope unit="vol">19</biblScope><biblScope unit="issue">12</biblScope><biblScope unit="page" from="1391">1391</biblScope><biblScope unit="page" to="1402">1402</biblScope></imprint></monogr><idno type="istex">2C01987595DEF441D78B1D1D9A34624282EBF9BA</idno><idno type="DOI">10.1002/mds.20255</idno><idno type="ArticleID">MDS20255</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2004</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>We aimed to develop and validate a novel rating scale for multiple system atrophy (Unified Multiple System Atrophy Rating Scale ‐ UMSARS). The scale comprises the following components: Part I, historical, 12 items; Part II, motor examination, 14 items; Part III, autonomic examination; and Part IV, global disability scale. For validation purposes, 40 MSA patients were assessed in four centers by 4 raters per center (2 senior and 2 junior raters). The raters applied the UMSARS, as well as a range of other scales, including the Unified Parkinson's Disease Rating Scale (UPDRS) and the International Cooperative Ataxia Rating Scale (ICARS). Internal consistency was high for both UMSARS‐I (Crohnbach's alpha = 0.84) and UMSARS‐II (Crohnbach's alpha = 0.90) sections. The interrater reliability of most of the UMSARS‐I and ‐II items as well as of total UMSARS‐I and ‐II subscores was substantial (k (w) = 0.6–0.8) to excellent (k (w) > 0.8). UMSARS‐II correlated well with UPDRS‐III and ICARS (rs > 0.8). Depending on the degree of the patient's disability, completion of the entire UMSARS took 30 to 45 minutes. Based on our findings, the UMSARS appears to be a multidimensional, reliable, and valid scale for semiquantitative clinical assessments of MSA patients. © 2004 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Unified Multiple System Atrophy Rating Scale</term></item><item><term>validation</term></item><item><term>internal consistency</term></item><item><term>interrater reliability</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>Article category</head><item><term>Research Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2004-01-16">Received</change><change when="2004-02-17">Registration</change><change when="2004-12">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/2C01987595DEF441D78B1D1D9A34624282EBF9BA/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="120"><doi origin="wiley" registered="yes">10.1002/mds.v19:12</doi><numberingGroup><numbering type="journalVolume" number="19">19</numbering><numbering type="journalIssue">12</numbering></numberingGroup><coverDate startDate="2004-12">December 2004</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="10" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.20255</doi><idGroup><id type="unit" value="MDS20255"></id></idGroup><countGroup><count type="pageTotal" number="13"></count></countGroup><titleGroup><title type="articleCategory">Research Article</title><title type="tocHeading1">Research Articles</title></titleGroup><copyright ownership="thirdParty">Copyright © 2004 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2004-01-16"></event><event type="manuscriptRevised" date="2004-02-09"></event><event type="manuscriptAccepted" date="2004-02-17"></event><event type="firstOnline" date="2004-08-05"></event><event type="publishedOnlineFinalForm" date="2004-10-27"></event><event type="publishedOnlineAcceptedOrEarlyUnpaginated" date="2004-08-05"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.4.7 mode:FullText source:FullText result:FullText" date="2011-02-24"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">1391</numbering><numbering type="pageLast">1402</numbering></numberingGroup><correspondenceTo>Department of Neurology. University of Innsbruck, A‐6020 Innsbruck, Austria</correspondenceTo><objectNameGroup><objectName elementName="appendix">APPENDIX</objectName></objectNameGroup><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS20255.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="11"></count><count type="referenceTotal" number="31"></count><count type="wordTotal" number="6209"></count></countGroup><titleGroup><title type="main" xml:lang="en">Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS)</title><title type="short" xml:lang="en">UMSARS</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes" noteRef="#fn1"><personName><givenNames>Gregor K.</givenNames><familyName>Wenning</familyName><degrees>MD, PhD</degrees></personName><contactDetails><email>gregor.wenning@uibk.ac.at</email></contactDetails></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af2" noteRef="#fn1"><personName><givenNames>Franc̨ois</givenNames><familyName>Tison</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Klaus</givenNames><familyName>Seppi</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Cristina</givenNames><familyName>Sampaio</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Anja</givenNames><familyName>Diem</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au6" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Farid</givenNames><familyName>Yekhlef</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au7" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Imad</givenNames><familyName>Ghorayeb</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au8" creatorRole="author" affiliationRef="#af4"><personName><givenNames>Fabienne</givenNames><familyName>Ory</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au9" creatorRole="author" affiliationRef="#af4"><personName><givenNames>Monique</givenNames><familyName>Galitzky</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au10" creatorRole="author" affiliationRef="#af5"><personName><givenNames>Tommaso</givenNames><familyName>Scaravilli</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au11" creatorRole="author" affiliationRef="#af5"><personName><givenNames>Maria</givenNames><familyName>Bozi</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au12" creatorRole="author" affiliationRef="#af6"><personName><givenNames>Carlo</givenNames><familyName>Colosimo</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au13" creatorRole="author" affiliationRef="#af7"><personName><givenNames>Sid</givenNames><familyName>Gilman</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au14" creatorRole="author" affiliationRef="#af8"><personName><givenNames>Clifford W.</givenNames><familyName>Shults</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au15" creatorRole="author" affiliationRef="#af5"><personName><givenNames>Niall P.</givenNames><familyName>Quinn</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au16" creatorRole="author" affiliationRef="#af4"><personName><givenNames>Olivier</givenNames><familyName>Rascol</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au17" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Werner</givenNames><familyName>Poewe</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au18" creatorRole="author" noteRef="#fn2"><groupName>and the Multiple System Atrophy Study Group</groupName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="AT" type="organization"><unparsedAffiliation>Department of Neurology, University of Innsbruck, Austria</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="FR" type="organization"><unparsedAffiliation>Service de Neurologie, Hopital du Haut‐Leveque, Pessac, France</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="PT" type="organization"><unparsedAffiliation>Faculdade de Medicine de Lisboa, Hospital Santa Maria, Centro de Neurosciencas, Lisboa, Portugal</unparsedAffiliation></affiliation><affiliation xml:id="af4" countryCode="FR" type="organization"><unparsedAffiliation>Toulouse III University, Laboratoire de Pharmacologie, Faculte de Medecine, Toulouse, France</unparsedAffiliation></affiliation><affiliation xml:id="af5" countryCode="GB" type="organization"><unparsedAffiliation>University College London, Institute of Neurology, Queen Square, London, United Kingdom</unparsedAffiliation></affiliation><affiliation xml:id="af6" countryCode="IT" type="organization"><unparsedAffiliation>Dipartimento di Scienze Neurologiche, Universita' La Sapienza, Rome, Italy</unparsedAffiliation></affiliation><affiliation xml:id="af7" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, University of Michigan, Ann Arbor, Michigan, USA</unparsedAffiliation></affiliation><affiliation xml:id="af8" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurosciences, University of California San Diego School of Medicine, La Jolla, California, USA</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">Unified Multiple System Atrophy Rating Scale</keyword><keyword xml:id="kwd2">validation</keyword><keyword xml:id="kwd3">internal consistency</keyword><keyword xml:id="kwd4">interrater reliability</keyword></keywordGroup><fundingInfo><fundingAgency>EC</fundingAgency><fundingNumber>QLK6‐2000‐00661</fundingNumber></fundingInfo><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>We aimed to develop and validate a novel rating scale for multiple system atrophy (Unified Multiple System Atrophy Rating Scale ‐ UMSARS). The scale comprises the following components: Part I, historical, 12 items; Part II, motor examination, 14 items; Part III, autonomic examination; and Part IV, global disability scale. For validation purposes, 40 MSA patients were assessed in four centers by 4 raters per center (2 senior and 2 junior raters). The raters applied the UMSARS, as well as a range of other scales, including the Unified Parkinson's Disease Rating Scale (UPDRS) and the International Cooperative Ataxia Rating Scale (ICARS). Internal consistency was high for both UMSARS‐I (Crohnbach's alpha = 0.84) and UMSARS‐II (Crohnbach's alpha = 0.90) sections. The interrater reliability of most of the UMSARS‐I and ‐II items as well as of total UMSARS‐I and ‐II subscores was substantial (<i>k (w)</i> = 0.6–0.8) to excellent (<i>k (w)</i> > 0.8). UMSARS‐II correlated well with UPDRS‐III and ICARS (r<sub>s</sub> > 0.8). Depending on the degree of the patient's disability, completion of the entire UMSARS took 30 to 45 minutes. Based on our findings, the UMSARS appears to be a multidimensional, reliable, and valid scale for semiquantitative clinical assessments of MSA patients. © 2004 Movement Disorder Society</p></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="fn1"><p>Drs. Wenning and Tison contributed equally to this study.</p></note><note xml:id="fn2"><p>See Acknowledgments for a full list of study participants.</p></note></noteGroup></header></component></istex:document></istex:metadataXml><!--Version 0.6 générée le 3-12-2015--><mods version="3.6"><titleInfo lang="en"><title>Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS)</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>UMSARS</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS)</title></titleInfo><name type="personal"><namePart type="given">Gregor K.</namePart><namePart type="family">Wenning</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Department of Neurology, University of Innsbruck, Austria</affiliation><description>Drs. Wenning and Tison contributed equally to this study.</description><description>Correspondence: Department of Neurology. University of Innsbruck, A‐6020 Innsbruck, Austria</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Franc̨ois</namePart><namePart type="family">Tison</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Service de Neurologie, Hopital du Haut‐Leveque, Pessac, France</affiliation><description>Drs. Wenning and Tison contributed equally to this study.</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Klaus</namePart><namePart type="family">Seppi</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, University of Innsbruck, Austria</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Cristina</namePart><namePart type="family">Sampaio</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Faculdade de Medicine de Lisboa, Hospital Santa Maria, Centro de Neurosciencas, Lisboa, Portugal</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Anja</namePart><namePart type="family">Diem</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, University of Innsbruck, Austria</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Farid</namePart><namePart type="family">Yekhlef</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Service de Neurologie, Hopital du Haut‐Leveque, Pessac, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Imad</namePart><namePart type="family">Ghorayeb</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Service de Neurologie, Hopital du Haut‐Leveque, Pessac, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Fabienne</namePart><namePart type="family">Ory</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Toulouse III University, Laboratoire de Pharmacologie, Faculte de Medecine, Toulouse, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Monique</namePart><namePart type="family">Galitzky</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Toulouse III University, Laboratoire de Pharmacologie, Faculte de Medecine, Toulouse, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Tommaso</namePart><namePart type="family">Scaravilli</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>University College London, Institute of Neurology, Queen Square, London, United Kingdom</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Maria</namePart><namePart type="family">Bozi</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>University College London, Institute of Neurology, Queen Square, London, United Kingdom</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Carlo</namePart><namePart type="family">Colosimo</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Dipartimento di Scienze Neurologiche, Universita' La Sapienza, Rome, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Sid</namePart><namePart type="family">Gilman</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, University of Michigan, Ann Arbor, Michigan, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Clifford W.</namePart><namePart type="family">Shults</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurosciences, University of California San Diego School of Medicine, La Jolla, California, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Niall P.</namePart><namePart type="family">Quinn</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>University College London, Institute of Neurology, Queen Square, London, United Kingdom</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Olivier</namePart><namePart type="family">Rascol</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Toulouse III University, Laboratoire de Pharmacologie, Faculte de Medecine, Toulouse, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Werner</namePart><namePart type="family">Poewe</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, University of Innsbruck, Austria</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="corporate"><namePart>and the Multiple System Atrophy Study Group</namePart><affiliation>Department of Neurology, University of Innsbruck, Austria</affiliation><affiliation>Service de Neurologie, Hopital du Haut‐Leveque, Pessac, France</affiliation><affiliation>Faculdade de Medicine de Lisboa, Hospital Santa Maria, Centro de Neurosciencas, Lisboa, Portugal</affiliation><affiliation>Toulouse III University, Laboratoire de Pharmacologie, Faculte de Medecine, Toulouse, France</affiliation><affiliation>University College London, Institute of Neurology, Queen Square, London, United Kingdom</affiliation><affiliation>Dipartimento di Scienze Neurologiche, Universita' La Sapienza, Rome, Italy</affiliation><affiliation>Department of Neurology, University of Michigan, Ann Arbor, Michigan, USA</affiliation><affiliation>Department of Neurosciences, University of California San Diego School of Medicine, La Jolla, California, USA</affiliation><description>Department of Neurology, University of Innsbruck, AustriaService de Neurologie, Hopital du Haut‐Leveque, Pessac, FranceFaculdade de Medicine de Lisboa, Hospital Santa Maria, Centro de Neurosciencas, Lisboa, PortugalToulouse III University, Laboratoire de Pharmacologie, Faculte de Medecine, Toulouse, FranceUniversity College London, Institute of Neurology, Queen Square, London, United KingdomDipartimento di Scienze Neurologiche, Universita' La Sapienza, Rome, ItalyDepartment of Neurology, University of Michigan, Ann Arbor, Michigan, USADepartment of Neurosciences, University of California San Diego School of Medicine, La Jolla, California, USA</description></name><typeOfResource>text</typeOfResource><genre authority="originalCategForm">article</genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2004-12</dateIssued><dateCaptured encoding="w3cdtf">2004-01-16</dateCaptured><dateValid encoding="w3cdtf">2004-02-17</dateValid><copyrightDate encoding="w3cdtf">2004</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="tables">11</extent><extent unit="references">31</extent><extent unit="words">6209</extent></physicalDescription><abstract lang="en">We aimed to develop and validate a novel rating scale for multiple system atrophy (Unified Multiple System Atrophy Rating Scale ‐ UMSARS). The scale comprises the following components: Part I, historical, 12 items; Part II, motor examination, 14 items; Part III, autonomic examination; and Part IV, global disability scale. For validation purposes, 40 MSA patients were assessed in four centers by 4 raters per center (2 senior and 2 junior raters). The raters applied the UMSARS, as well as a range of other scales, including the Unified Parkinson's Disease Rating Scale (UPDRS) and the International Cooperative Ataxia Rating Scale (ICARS). Internal consistency was high for both UMSARS‐I (Crohnbach's alpha = 0.84) and UMSARS‐II (Crohnbach's alpha = 0.90) sections. The interrater reliability of most of the UMSARS‐I and ‐II items as well as of total UMSARS‐I and ‐II subscores was substantial (k (w) = 0.6–0.8) to excellent (k (w) > 0.8). UMSARS‐II correlated well with UPDRS‐III and ICARS (rs > 0.8). Depending on the degree of the patient's disability, completion of the entire UMSARS took 30 to 45 minutes. Based on our findings, the UMSARS appears to be a multidimensional, reliable, and valid scale for semiquantitative clinical assessments of MSA patients. © 2004 Movement Disorder Society</abstract><note type="funding">EC - No. QLK6‐2000‐00661; </note><subject lang="en"><genre>Keywords</genre><topic>Unified Multiple System Atrophy Rating Scale</topic><topic>validation</topic><topic>internal consistency</topic><topic>interrater reliability</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><subject><genre>article category</genre><topic>Research Article</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>19</number></detail><detail type="issue"><caption>no.</caption><number>12</number></detail><extent unit="pages"><start>1391</start><end>1402</end><total>13</total></extent></part></relatedItem><identifier type="istex">2C01987595DEF441D78B1D1D9A34624282EBF9BA</identifier><identifier type="DOI">10.1002/mds.20255</identifier><identifier type="ArticleID">MDS20255</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2004 Movement Disorder Society</accessCondition><recordInfo><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin><recordContentSource>WILEY</recordContentSource></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000613 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000613 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:2C01987595DEF441D78B1D1D9A34624282EBF9BA
|texte= Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS)
}}
| This area was generated with Dilib version V0.6.23. |  |